Because FLT3-mutated AML has a higher risk of relapse than FLT3-mutation-negative AML, the addition of midostaurin maintenance therapy post-HSCT may be a viable option to reduce the risk of relapse in some patients after alloHSCT. Here, FLT3 is linked to acute myeloid leukemia.